SLCO1B1 variants and the risk of antituberculosis drug-induced hepatotoxicity : a systematic review and meta-analysis
Aims: To evaluate the association between SLCO1B1 gene polymorphisms and susceptibility of antituberculosis drug-induced hepatotoxicity (ATDH). Methods: We searched the PubMed, Cochrane Library, Embase, Web of Science, Wan Fang and China National Knowledge Infrastructure database from inception to 2022. Results: Nine case-control studies with 1129 cases and 2203 controls were included. Among four SNPs reported in two or more studies, the final results indicated that SNP rs4149014 was significantly associated with decreased ATDH risk (dominant model, odds ratio: 0.73; 95% CI: 0.55-0.97; p = 0.03; allele model, odds ratio: 0.69; 95% CI: 0.55-0.86; p = 0.001), and the trial sequential analysis also confirmed this significant association. Conclusion: SLCO1B1 gene SNP rs4149014 was significantly associated with lower risk of ATDH susceptibility.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 24(2023), 18 vom: 01. Dez., Seite 931-942 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhu, Min [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.12.2023 Date Revised 22.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/pgs-2023-0168 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365102644 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365102644 | ||
| 003 | DE-627 | ||
| 005 | 20231227135952.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2023-0168 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1235.xml |
| 035 | |a (DE-627)NLM365102644 | ||
| 035 | |a (NLM)38019119 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhu, Min |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a SLCO1B1 variants and the risk of antituberculosis drug-induced hepatotoxicity |b a systematic review and meta-analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.12.2023 | ||
| 500 | |a Date Revised 22.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aims: To evaluate the association between SLCO1B1 gene polymorphisms and susceptibility of antituberculosis drug-induced hepatotoxicity (ATDH). Methods: We searched the PubMed, Cochrane Library, Embase, Web of Science, Wan Fang and China National Knowledge Infrastructure database from inception to 2022. Results: Nine case-control studies with 1129 cases and 2203 controls were included. Among four SNPs reported in two or more studies, the final results indicated that SNP rs4149014 was significantly associated with decreased ATDH risk (dominant model, odds ratio: 0.73; 95% CI: 0.55-0.97; p = 0.03; allele model, odds ratio: 0.69; 95% CI: 0.55-0.86; p = 0.001), and the trial sequential analysis also confirmed this significant association. Conclusion: SLCO1B1 gene SNP rs4149014 was significantly associated with lower risk of ATDH susceptibility | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a SLCO1B1 | |
| 650 | 4 | |a antituberculosis drug-induced hepatotoxicity | |
| 650 | 4 | |a meta-analysis | |
| 650 | 4 | |a single nucleotide polymorphism | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 650 | 7 | |a SLCO1B1 protein, human |2 NLM | |
| 650 | 7 | |a Liver-Specific Organic Anion Transporter 1 |2 NLM | |
| 700 | 1 | |a Chen, Xinyu |e verfasserin |4 aut | |
| 700 | 1 | |a Hao, Zhuolu |e verfasserin |4 aut | |
| 700 | 1 | |a He, Yiwen |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Bing |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Shaowen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 24(2023), 18 vom: 01. Dez., Seite 931-942 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:18 |g day:01 |g month:12 |g pages:931-942 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2023-0168 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 18 |b 01 |c 12 |h 931-942 | ||